This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Aerie Pharmaceuticals Future Growth
Future criteria checks 4/6
Key information
67.5%
Earnings growth rate
78.2%
EPS growth rate
| Pharmaceuticals earnings growth | 21.7% |
| Revenue growth rate | 19.3% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | n/a |
Recent future growth updates
Recent updates
Alcon to acquire Aerie Pharmaceuticals at ~$770M, enhancing its ophthalmic pharmaceutical portfolio
Aug 23Aerie Pharmaceuticals grants 16.9K stock options
Aug 15Aerie Pharma rises 14% after Q2 result beat on higher glaucoma franchise sales
Aug 05Aerie Pharma completes enrollment in first Phase 3 trial of netarsudil in Japan
Jun 17Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability
Feb 27
Who Has Been Selling Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Shares?
Jan 28Aerie Pharmaceuticals receives European approval for Roclanda
Jan 11Aerie Pharmaceuticals (NASDAQ:AERI) Share Prices Have Dropped 76% In The Last Three Years
Dec 24Is Aerie Pharmaceuticals (NASDAQ:AERI) A Risky Investment?
Nov 28
European advisory group backs Aerie Pharma's Roclanda
Nov 13Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | 226 | -26 | -2 | 41 | 8 |
| 12/31/2023 | 180 | -64 | -56 | 6 | 10 |
| 12/31/2022 | 138 | -123 | -89 | -1 | 5 |
| 9/30/2022 | 214 | -37 | 3 | 7 | N/A |
| 6/30/2022 | 207 | -49 | -5 | 0 | N/A |
| 3/31/2022 | 201 | -69 | -11 | -7 | N/A |
| 12/31/2021 | 194 | -75 | -102 | -99 | N/A |
| 9/30/2021 | 104 | -166 | -50 | -47 | N/A |
| 6/30/2021 | 95 | -166 | -53 | -50 | N/A |
| 3/31/2021 | 86 | -176 | -56 | -53 | N/A |
| 12/31/2020 | 83 | -183 | -68 | -65 | N/A |
| 9/30/2020 | 83 | -192 | -127 | -114 | N/A |
| 6/30/2020 | 82 | -202 | -142 | -130 | N/A |
| 3/31/2020 | 79 | -201 | -158 | -144 | N/A |
| 12/31/2019 | 70 | -200 | -168 | -150 | N/A |
| 9/30/2019 | 60 | -196 | -165 | -155 | N/A |
| 6/30/2019 | 48 | -232 | -175 | -160 | N/A |
| 3/31/2019 | 35 | -240 | -188 | -160 | N/A |
| 12/31/2018 | 24 | -233 | -184 | -153 | N/A |
| 9/30/2018 | 10 | -240 | -196 | -147 | N/A |
| 6/30/2018 | 2 | -187 | -172 | -125 | N/A |
| 3/31/2018 | N/A | -160 | -144 | -109 | N/A |
| 12/31/2017 | N/A | -145 | -120 | -93 | N/A |
| 9/30/2017 | N/A | -116 | -97 | -86 | N/A |
| 6/30/2017 | N/A | -107 | -93 | -86 | N/A |
| 3/31/2017 | N/A | -102 | -91 | -85 | N/A |
| 12/31/2016 | N/A | -99 | -85 | -80 | N/A |
| 9/30/2016 | N/A | -90 | -78 | -75 | N/A |
| 6/30/2016 | N/A | -84 | N/A | -66 | N/A |
| 3/31/2016 | N/A | -80 | N/A | -62 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AERI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: AERI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AERI is expected to become profitable in the next 3 years.
Revenue vs Market: AERI's revenue (19.3% per year) is forecast to grow faster than the US market (6.9% per year).
High Growth Revenue: AERI's revenue (19.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AERI's Return on Equity is forecast to be high in 3 years time